Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Second-generation oral cephalosporin

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list second- and third-generation cephalosporins among antibiotics that can potentiate acenocoumarol. The cefuroxime SmPC classifies cefuroxime (cefuroxime axetil) as a second-generation cephalosporin (acenocoumarol and cefuroxime SmPCs, AEMPS). According to the cefuroxime SmPC, use with oral anticoagulants can raise the INR. The documents do not explain how this happens (AEMPS). The US label for cefuroxime axetil lists prolonged prothrombin time among post-marketing reports (cefuroxime axetil prescribing information, US Food and Drug Administration, FDA). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. According to the cefuroxime summary of product characteristics (SmPC), use with oral anticoagulants can raise the international normalised ratio (INR). Thrombocytopenia is among the uncommon adverse effects of cefuroxime itself (cefuroxime SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label for cefuroxime axetil lists prolonged prothrombin time and thrombocytopenia among post-marketing reports (cefuroxime axetil prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) ask for close and frequent coagulation checks, for example twice a week. This applies both when cefuroxime is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The cefuroxime SmPC only states that use with oral anticoagulants can raise the international normalised ratio (INR) and gives no specific measures (cefuroxime SmPC, AEMPS). The US cefuroxime axetil label does not list anticoagulants among its interactions (US Food and Drug Administration, FDA). Adjust the acenocoumarol dose by the prothrombin time and the INR. A dose change does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. After bleeding, restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol